Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""mutations"" wg kryterium: Temat


Tytuł :
Targeting "undruggable" c-Myc protein by synthetic lethality.
Autorzy :
Wang C; Division of Genome Medicine and Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China.; Institute of Genetics, Zhejiang University and Department of Genetics, Zhejiang University School of Medicine, Hangzhou, 310058, China.; Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou, 311121, China.
Fang H; Institute of Genetics, Zhejiang University and Department of Genetics, Zhejiang University School of Medicine, Hangzhou, 310058, China.
Zhang J; Division of Genome Medicine and Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China. .
Gu Y; Division of Genome Medicine and Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China. .; Institute of Genetics, Zhejiang University and Department of Genetics, Zhejiang University School of Medicine, Hangzhou, 310058, China. .; Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou, 311121, China. .
Pokaż więcej
Źródło :
Frontiers of medicine [Front Med] 2021 Aug; Vol. 15 (4), pp. 541-550. Date of Electronic Publication: 2021 Mar 04.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Neoplasms*/drug therapy
Neoplasms*/genetics
Synthetic Lethal Mutations*
Humans ; Mutation ; Proteins ; Proto-Oncogene Proteins c-myc/genetics
Czasopismo naukowe
Tytuł :
KG4SL: knowledge graph neural network for synthetic lethality prediction in human cancers.
Autorzy :
Wang S; School of Information Science and Technology, ShanghaiTech University, Shanghai 201210, China.
Xu F; School of Information Science and Technology, ShanghaiTech University, Shanghai 201210, China.
Li Y; School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.
Wang J; School of Information Science and Technology, ShanghaiTech University, Shanghai 201210, China.
Zhang K; School of Information Science and Technology, ShanghaiTech University, Shanghai 201210, China.; Shanghai Institute of Microsystem and Information Technology, Chinese Academy of Sciences, Shanghai 200050, China.
Liu Y; Joint NTU-UBC Research Centre of Excellence in Active Living for the Elderly, Nanyang Technological University, Singapore 639798, Singapore.
Wu M; Institute for Infocomm Research, Agency for Science, Technology and Research (A*STAR), Singapore 138632, Singapore.
Zheng J; School of Information Science and Technology, ShanghaiTech University, Shanghai 201210, China.; Shanghai Engineering Research Center of Intelligent Vision and Imaging, Shanghai, 201210, China.
Pokaż więcej
Źródło :
Bioinformatics (Oxford, England) [Bioinformatics] 2021 Jul 12; Vol. 37 (Suppl_1), pp. i418-i425.
Typ publikacji :
Journal Article
MeSH Terms :
Neoplasms*/genetics
Synthetic Lethal Mutations*
Humans ; Neural Networks, Computer ; Pattern Recognition, Automated ; Proteomics
Czasopismo naukowe
Tytuł :
SynLeGG: analysis and visualization of multiomics data for discovery of cancer 'Achilles Heels' and gene function relationships.
Autorzy :
Wappett M; Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast BT9 7AE, UK.; Drug Discovery, Almac Discovery Ltd, Belfast BT9 7AE, UK.
Harris A; Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast BT9 7AE, UK.
Lubbock ALR; Department of Biochemistry, Vanderbilt University, Nashville, TN 37232, USA.
Lobb I; Drug Discovery, Almac Discovery Ltd, Belfast BT9 7AE, UK.
McDade S; Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast BT9 7AE, UK.
Overton IM; Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast BT9 7AE, UK.
Pokaż więcej
Źródło :
Nucleic acids research [Nucleic Acids Res] 2021 Jul 02; Vol. 49 (W1), pp. W613-W618.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Genes, Neoplasm*
Software*
Synthetic Lethal Mutations*
Neoplasms/*genetics
CRISPR-Cas Systems ; Cell Line, Tumor ; Gene Expression ; Gene Expression Profiling ; Humans ; Mutation ; Proteomics
Czasopismo naukowe
Tytuł :
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.
Autorzy :
Zatreanu D; CRUK Gene Function Laboratory, The Institute of Cancer Research, London, UK.; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Robinson HMR; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Alkhatib O; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Boursier M; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Finch H; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Geo L; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Grande D; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Grinkevich V; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Heald RA; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Langdon S; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Majithiya J; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
McWhirter C; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Martin NMB; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Moore S; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Neves J; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Rajendra E; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Ranzani M; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Schaedler T; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Stockley M; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Wiggins K; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Brough R; CRUK Gene Function Laboratory, The Institute of Cancer Research, London, UK.; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Sridhar S; CRUK Gene Function Laboratory, The Institute of Cancer Research, London, UK.; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Gulati A; CRUK Gene Function Laboratory, The Institute of Cancer Research, London, UK.; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Shao N; CRUK Gene Function Laboratory, The Institute of Cancer Research, London, UK.; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Badder LM; The Breast Cancer Now Research Unit, King's College London, London, UK.
Novo D; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Knight EG; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Marlow R; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.; The Breast Cancer Now Research Unit, King's College London, London, UK.
Haider S; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Callen E; Laboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD, USA.
Hewitt G; The Francis Crick Institute, London, UK.
Schimmel J; Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
Prevo R; Medical Research Council Oxford Institute for Radiation Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, UK.
Alli C; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Ferdinand A; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Bell C; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Blencowe P; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Bot C; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Calder M; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Charles M; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Curry J; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Ekwuru T; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Ewings K; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Krajewski W; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
MacDonald E; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
McCarron H; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Pang L; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Pedder C; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Rigoreau L; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Swarbrick M; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Wheatley E; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Willis S; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Wong AC; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Nussenzweig A; Laboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD, USA.
Tijsterman M; Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
Tutt A; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.; The Breast Cancer Now Research Unit, King's College London, London, UK.
Boulton SJ; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.; The Francis Crick Institute, London, UK.
Higgins GS; Medical Research Council Oxford Institute for Radiation Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, UK.
Pettitt SJ; CRUK Gene Function Laboratory, The Institute of Cancer Research, London, UK. .; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK. .
Smith GCM; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK. .
Lord CJ; CRUK Gene Function Laboratory, The Institute of Cancer Research, London, UK. .; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2021 Jun 17; Vol. 12 (1), pp. 3636. Date of Electronic Publication: 2021 Jun 17.
Typ publikacji :
Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
MeSH Terms :
BRCA1 Protein/*genetics
BRCA2 Protein/*genetics
DNA Repair/*drug effects
DNA-Directed DNA Polymerase/*genetics
Nucleic Acid Synthesis Inhibitors/*pharmacology
Poly(ADP-ribose) Polymerase Inhibitors/*pharmacology
Synthetic Lethal Mutations/*drug effects
Allosteric Regulation ; Animals ; Apoptosis/drug effects ; Apoptosis/genetics ; BRCA1 Protein/metabolism ; BRCA2 Protein/metabolism ; Cell Cycle Proteins/metabolism ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Proliferation/genetics ; Cell Survival/drug effects ; Cell Survival/radiation effects ; DNA Damage/drug effects ; DNA-Binding Proteins/metabolism ; DNA-Directed DNA Polymerase/metabolism ; Deoxyribonucleases/antagonists & inhibitors ; Drug Resistance, Neoplasm ; Drug Screening Assays, Antitumor ; Female ; Homologous Recombination/drug effects ; Humans ; Inhibitory Concentration 50 ; Mice ; Organoids/drug effects ; Ovarian Neoplasms/genetics ; Rats ; Synthetic Lethal Mutations/genetics ; Tumor Suppressor p53-Binding Protein 1/deficiency ; Tumor Suppressor p53-Binding Protein 1/metabolism
Czasopismo naukowe
Tytuł :
FANCM regulates repair pathway choice at stalled replication forks.
Autorzy :
Panday A; Department of Medicine, Division of Hematology-Oncology and Cancer Research Institute, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA 02215, USA.
Willis NA; Department of Medicine, Division of Hematology-Oncology and Cancer Research Institute, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA 02215, USA.
Elango R; Department of Medicine, Division of Hematology-Oncology and Cancer Research Institute, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA 02215, USA.
Menghi F; The Jackson Laboratory for Genomic Medicine, Farmington, CT 06030, USA.
Duffey EE; Department of Medicine, Division of Hematology-Oncology and Cancer Research Institute, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA 02215, USA.
Liu ET; The Jackson Laboratory for Genomic Medicine, Farmington, CT 06030, USA.
Scully R; Department of Medicine, Division of Hematology-Oncology and Cancer Research Institute, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA 02215, USA. Electronic address: .
Pokaż więcej
Źródło :
Molecular cell [Mol Cell] 2021 Jun 03; Vol. 81 (11), pp. 2428-2444.e6. Date of Electronic Publication: 2021 Apr 20.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
DNA Repair*
DNA Replication*
Synthetic Lethal Mutations*
BRCA1 Protein/*genetics
DNA Helicases/*genetics
Mouse Embryonic Stem Cells/*metabolism
Animals ; BRCA1 Protein/metabolism ; Cell Cycle/genetics ; Cell Line ; Clone Cells ; DNA Helicases/metabolism ; Fanconi Anemia Complementation Group D2 Protein/genetics ; Fanconi Anemia Complementation Group D2 Protein/metabolism ; Fibroblasts/cytology ; Fibroblasts/metabolism ; Humans ; Mice ; Mouse Embryonic Stem Cells/cytology ; Ubiquitination
Czasopismo naukowe
Tytuł :
CCNE1 Is a Putative Therapeutic Target for ARID1A -Mutated Ovarian Clear Cell Carcinoma.
Autorzy :
Kawahara N; Department of Obstetrics and Gynecology, Nara Medical University, Nara 634-8521, Japan.
Yamada Y; Department of Obstetrics and Gynecology, Nara Medical University, Nara 634-8521, Japan.
Kobayashi H; Department of Obstetrics and Gynecology, Nara Medical University, Nara 634-8521, Japan.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 May 30; Vol. 22 (11). Date of Electronic Publication: 2021 May 30.
Typ publikacji :
Journal Article
MeSH Terms :
Synthetic Lethal Mutations*
Adenocarcinoma, Clear Cell/*genetics
Cyclin E/*genetics
DNA-Binding Proteins/*genetics
Oncogene Proteins/*genetics
Ovarian Neoplasms/*genetics
Transcription Factors/*genetics
Adenocarcinoma, Clear Cell/metabolism ; Adenocarcinoma, Clear Cell/pathology ; Animals ; Antineoplastic Agents/pharmacology ; Apoptosis/drug effects ; Apoptosis/genetics ; Cell Cycle/drug effects ; Cell Cycle/genetics ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cisplatin/pharmacology ; Cyclin E/antagonists & inhibitors ; Cyclin E/metabolism ; DNA-Binding Proteins/antagonists & inhibitors ; DNA-Binding Proteins/metabolism ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Mice ; Mice, Nude ; Molecular Targeted Therapy ; Oncogene Proteins/antagonists & inhibitors ; Oncogene Proteins/metabolism ; Ovarian Neoplasms/metabolism ; Ovarian Neoplasms/pathology ; RNA, Small Interfering/genetics ; RNA, Small Interfering/metabolism ; Transcription Factors/antagonists & inhibitors ; Transcription Factors/metabolism ; Tumor Burden/drug effects ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Breast Cancer Predisposition Genes and Synthetic Lethality.
Autorzy :
Neiger HE; College of Graduate Studies, California Northstate University, Elk Grove, CA 95757, USA.
Siegler EL; College of Medicine, California Northstate University, Elk Grove, CA 95757, USA.
Shi Y; College of Medicine, California Northstate University, Elk Grove, CA 95757, USA.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 May 25; Vol. 22 (11). Date of Electronic Publication: 2021 May 25.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Genetic Predisposition to Disease*
Synthetic Lethal Mutations*
BRCA1 Protein/*genetics
BRCA2 Protein/*genetics
Breast Neoplasms/*genetics
Fanconi Anemia Complementation Group N Protein/*genetics
Breast Neoplasms/therapy ; DNA Repair ; Female ; Humans
Czasopismo naukowe
Tytuł :
The haplolethality paradox of the wupA gene in Drosophila.
Autorzy :
Casas-Tintó S; Instituto Cajal, Consejo Superior de Investigaciones Científicas, Madrid, Spain.
Ferrús A; Instituto Cajal, Consejo Superior de Investigaciones Científicas, Madrid, Spain.
Pokaż więcej
Źródło :
PLoS genetics [PLoS Genet] 2021 Mar 19; Vol. 17 (3), pp. e1009108. Date of Electronic Publication: 2021 Mar 19 (Print Publication: 2021).
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Haplotypes*
Synthetic Lethal Mutations*
Drosophila/*genetics
Drosophila Proteins/*genetics
Troponin I/*genetics
Animals ; Chromosome Duplication ; Chromosome Mapping ; Female ; Gene Expression Regulation ; Genetic Association Studies ; Male ; Phenotype
Czasopismo naukowe
Tytuł :
Capitalizing on Synthetic Lethality of MYC to Treat Cancer in the Digital Age.
Autorzy :
Thng DKH; Cancer Science Institute of Singapore, National University of Singapore, Singapore.
Toh TB; The N.1 Institute for Health, National University of Singapore, Singapore; The Institute for Digital Medicine (WisDM), Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Chow EK; Cancer Science Institute of Singapore, National University of Singapore, Singapore; The N.1 Institute for Health, National University of Singapore, Singapore; The Institute for Digital Medicine (WisDM), Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Department of Biomedical Engineering, National University of Singapore, Singapore. Electronic address: .
Pokaż więcej
Źródło :
Trends in pharmacological sciences [Trends Pharmacol Sci] 2021 Mar; Vol. 42 (3), pp. 166-182. Date of Electronic Publication: 2021 Jan 06.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Neoplasms*/drug therapy
Neoplasms*/genetics
Proto-Oncogene Proteins c-myc*/genetics
Synthetic Lethal Mutations*
Humans ; Oncogenes
Czasopismo naukowe
Tytuł :
A Novel cytarabine analog evokes synthetic lethality by targeting MK2 in p53-deficient cancer cells.
Autorzy :
Song J; College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea.
Yu J; College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea.
Jeong LS; College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea.
Lee SK; College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea. Electronic address: .
Pokaż więcej
Źródło :
Cancer letters [Cancer Lett] 2021 Jan 28; Vol. 497, pp. 54-65. Date of Electronic Publication: 2020 Oct 16.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Synthetic Lethal Mutations*
Biomarkers, Tumor/*metabolism
Cytarabine/*analogs & derivatives
Gene Expression Regulation, Neoplastic/*drug effects
Intracellular Signaling Peptides and Proteins/*metabolism
Prostatic Neoplasms/*drug therapy
Protein-Serine-Threonine Kinases/*metabolism
Tumor Suppressor Protein p53/*metabolism
Animals ; Antimetabolites, Antineoplastic/chemistry ; Antimetabolites, Antineoplastic/pharmacology ; Apoptosis ; Biomarkers, Tumor/genetics ; Cell Cycle Checkpoints ; Cell Movement ; Cell Proliferation ; Cytarabine/pharmacology ; DNA Damage ; DNA Repair ; Humans ; Intracellular Signaling Peptides and Proteins/genetics ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Prostatic Neoplasms/metabolism ; Prostatic Neoplasms/pathology ; Protein-Serine-Threonine Kinases/genetics ; Tumor Cells, Cultured ; Tumor Suppressor Protein p53/genetics ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Synthetic lethality between MyD88 loss and mutations in Wnt/β-catenin pathway in intestinal tumor epithelial cells.
Autorzy :
Kajino-Sakamoto R; Division of Pathophysiology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan.
Fujishita T; Division of Pathophysiology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan.
Taketo MM; Division of Experimental Therapeutics, Graduate School of Medicine, Kyoto University, Yoshida-Konoé-cho, Sakyo-ku, Kyoto, 606-8501, Japan.
Aoki M; Division of Pathophysiology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan. .; Department of Cancer Physiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 464-8550, Japan. .
Pokaż więcej
Źródło :
Oncogene [Oncogene] 2021 Jan; Vol. 40 (2), pp. 408-420. Date of Electronic Publication: 2020 Nov 12.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Synthetic Lethal Mutations*
Intestinal Mucosa/*pathology
Intestinal Neoplasms/*pathology
Myeloid Differentiation Factor 88/*physiology
Wnt Proteins/*genetics
beta Catenin/*genetics
Animals ; Apoptosis ; Cell Proliferation ; Cells, Cultured ; Female ; Intestinal Mucosa/metabolism ; Intestinal Neoplasms/genetics ; Intestinal Neoplasms/metabolism ; Mice ; Mice, Inbred C57BL ; Mice, Knockout
Czasopismo naukowe
Tytuł :
PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Autorzy :
Gralewska P; Department of Medical Biophysics, Faculty of Biology and Environmental Protection, Institute of Biophysics, University of Lodz, 90-236 Lodz, Poland.
Gajek A; Department of Medical Biophysics, Faculty of Biology and Environmental Protection, Institute of Biophysics, University of Lodz, 90-236 Lodz, Poland.
Marczak A; Department of Medical Biophysics, Faculty of Biology and Environmental Protection, Institute of Biophysics, University of Lodz, 90-236 Lodz, Poland.
Mikuła M; Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
Ostrowski J; Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.; Department of Gastroenterology, Hepatology and Clinical Oncology, Centre of Postgraduate Medical Education, 01-813 Warsaw, Poland.
Śliwińska A; Department of Nucleic Acid Biochemistry, Medical University of Lodz, 92-213 Lodz, Poland.
Rogalska A; Department of Medical Biophysics, Faculty of Biology and Environmental Protection, Institute of Biophysics, University of Lodz, 90-236 Lodz, Poland.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2020 Dec 19; Vol. 21 (24). Date of Electronic Publication: 2020 Dec 19.
Typ publikacji :
Journal Article
MeSH Terms :
Homologous Recombination*
Synthetic Lethal Mutations*
Ataxia Telangiectasia Mutated Proteins/*antagonists & inhibitors
Checkpoint Kinase 1/*antagonists & inhibitors
Cystadenocarcinoma, Serous/*pathology
Ovarian Neoplasms/*pathology
Poly(ADP-ribose) Polymerase Inhibitors/*pharmacology
Ataxia Telangiectasia Mutated Proteins/genetics ; Ataxia Telangiectasia Mutated Proteins/metabolism ; BRCA1 Protein/genetics ; BRCA2 Protein/genetics ; Checkpoint Kinase 1/genetics ; Checkpoint Kinase 1/metabolism ; Cystadenocarcinoma, Serous/drug therapy ; Cystadenocarcinoma, Serous/genetics ; Female ; Humans ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/genetics ; RNA, Small Interfering/genetics ; Signal Transduction
Czasopismo naukowe
Tytuł :
Precise single base substitution in the shibire gene by CRISPR/Cas9-mediated homology directed repair in Bactrocera tryoni.
Autorzy :
Choo A; School of Biological Sciences, University of Adelaide, Adelaide, SA, Australia. .
Fung E; South Australian Research and Development Institute (SARDI), Adelaide, SA, Australia.
Chen IY; School of Biological Sciences, University of Adelaide, Adelaide, SA, Australia.
Saint R; Flinders University, Adelaide, SA, Australia.
Crisp P; South Australian Research and Development Institute (SARDI), Adelaide, SA, Australia.; School of Agriculture, Food and Wine, University of Adelaide, Adelaide, SA, Australia.
Baxter SW; School of BioSciences, University of Melbourne, Melbourne, Australia.
Pokaż więcej
Źródło :
BMC genetics [BMC Genet] 2020 Dec 18; Vol. 21 (Suppl 2), pp. 127. Date of Electronic Publication: 2020 Dec 18.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
CRISPR-Cas Systems*
Point Mutation*
Synthetic Lethal Mutations*
Tephritidae/*genetics
Alleles ; Amino Acid Sequence ; Animals ; Australia ; Genetic Fitness ; Genotype ; Insect Control ; Phenotype ; Sequence Alignment ; Temperature
Czasopismo naukowe
Tytuł :
Synthetic Lethality through the Lens of Medicinal Chemistry.
Autorzy :
Myers SH; Computational & Chemical Biology, Istituto Italiano di Tecnologia, 16163 Genova, Italy.
Ortega JA; Computational & Chemical Biology, Istituto Italiano di Tecnologia, 16163 Genova, Italy.
Cavalli A; Computational & Chemical Biology, Istituto Italiano di Tecnologia, 16163 Genova, Italy.; Department of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy.
Pokaż więcej
Źródło :
Journal of medicinal chemistry [J Med Chem] 2020 Dec 10; Vol. 63 (23), pp. 14151-14183. Date of Electronic Publication: 2020 Nov 02.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Synthetic Lethal Mutations*
Ataxia Telangiectasia Mutated Proteins/genetics ; Cell Cycle Proteins/antagonists & inhibitors ; Cyclin-Dependent Kinases/antagonists & inhibitors ; DNA-Activated Protein Kinase/antagonists & inhibitors ; Genes, BRCA2 ; Humans ; Neoplasms/genetics ; Neoplasms/therapy ; Poly(ADP-ribose) Polymerases/genetics ; Precision Medicine ; Protein Kinase Inhibitors/pharmacology ; Protein-Tyrosine Kinases/antagonists & inhibitors ; Rad51 Recombinase/genetics
Czasopismo naukowe
Tytuł :
Leflunomide triggers synthetic lethality in PTEN-deficient prostate cancer.
Autorzy :
Ozturk S; Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Mathur D; Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.; Computational and Systems Biology Department, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Zhou RW; Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Mulholland D; Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Parsons R; Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. .
Pokaż więcej
Źródło :
Prostate cancer and prostatic diseases [Prostate Cancer Prostatic Dis] 2020 Dec; Vol. 23 (4), pp. 718-723. Date of Electronic Publication: 2020 Jul 13.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Synthetic Lethal Mutations*
Leflunomide/*toxicity
PTEN Phosphohydrolase/*deficiency
Prostatic Neoplasms/*pathology
Pyrimidines/*metabolism
Animals ; Cell Line ; Cell Line, Tumor ; Humans ; Immunosuppressive Agents/toxicity ; Male ; Mice ; Mice, Nude ; PTEN Phosphohydrolase/genetics ; PTEN Phosphohydrolase/metabolism ; Prostatic Neoplasms/chemically induced ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms/metabolism ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Synthetic lethal targeting of TET2-mutant hematopoietic stem and progenitor cells (HSPCs) with TOP1-targeted drugs and PARP1 inhibitors.
Autorzy :
Jing CB; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Fu C; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Prutsch N; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Wang M; Department of Dermatology and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
He S; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Look AT; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. .
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2020 Nov; Vol. 34 (11), pp. 2992-3006. Date of Electronic Publication: 2020 Jun 22.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Synthetic Lethal Mutations*
DNA Topoisomerases, Type I/*metabolism
DNA-Binding Proteins/*genetics
Hematopoietic Stem Cells/*drug effects
Hematopoietic Stem Cells/*metabolism
Poly (ADP-Ribose) Polymerase-1/*antagonists & inhibitors
Proto-Oncogene Proteins/*genetics
Topoisomerase I Inhibitors/*pharmacology
Animals ; Animals, Genetically Modified ; Antineoplastic Agents/pharmacology ; Apoptosis/drug effects ; Apoptosis/genetics ; Cell Survival/drug effects ; Cell Survival/genetics ; DNA Breaks, Double-Stranded/drug effects ; Genotype ; Humans ; Mice ; Mice, Knockout ; Phenotype ; Topotecan/pharmacology ; Zebrafish
Czasopismo naukowe
Tytuł :
Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation.
Autorzy :
Topatana W; Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University, Hangzhou, 310016, China.; School of Medicine, Zhejiang University, Hangzhou, 310058, China.
Juengpanich S; Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University, Hangzhou, 310016, China.; School of Medicine, Zhejiang University, Hangzhou, 310058, China.
Li S; Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University, Hangzhou, 310016, China.
Cao J; Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University, Hangzhou, 310016, China.
Hu J; Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University, Hangzhou, 310016, China.
Lee J; Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
Suliyanto K; School of Medicine, Zhejiang University, Hangzhou, 310058, China.
Ma D; School of Medicine, Zhejiang University, Hangzhou, 310058, China.
Zhang B; Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University, Hangzhou, 310016, China.
Chen M; Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University, Hangzhou, 310016, China. .; School of Medicine, Zhejiang University, Hangzhou, 310058, China. .
Cai X; Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University, Hangzhou, 310016, China. .; School of Medicine, Zhejiang University, Hangzhou, 310058, China. .; Key Laboratory of Endoscopic Technique Research of Zhejiang Province, No.3 East Qingchun Road, Hangzhou, 310016, China. .
Pokaż więcej
Źródło :
Journal of hematology & oncology [J Hematol Oncol] 2020 Sep 03; Vol. 13 (1), pp. 118. Date of Electronic Publication: 2020 Sep 03.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Synthetic Lethal Mutations*
Molecular Targeted Therapy/*methods
Neoplasms/*therapy
Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; CRISPR-Cas Systems ; Cell Cycle/drug effects ; Cell Survival/drug effects ; Cellular Senescence/drug effects ; DNA Damage/drug effects ; DNA Repair ; Drug Design ; Drug Resistance, Neoplasm ; Drug Screening Assays, Antitumor ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Mutation ; Neoplasm Proteins/antagonists & inhibitors ; Neoplasm Proteins/physiology ; Neoplasms/genetics ; Patient Selection ; Protein Folding ; RNA Interference ; Translational Medical Research ; Tumor Microenvironment
Czasopismo naukowe
Tytuł :
Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer.
Autorzy :
Hu Y; Department of Gastroenterology and Hepatology, Chinese PLA General Hospital, Beijing, China.
Guo M; Department of Gastroenterology and Hepatology, Chinese PLA General Hospital, Beijing, China.; Henan Key Laboratory for Esophageal Cancer Research, Zhengzhou University, Zhengzhou, China.; State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital, Beijing, China.
Pokaż więcej
Źródło :
Cancer science [Cancer Sci] 2020 Sep; Vol. 111 (9), pp. 3111-3121. Date of Electronic Publication: 2020 Aug 06.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Synthetic Lethal Mutations*
BRCA1 Protein/*genetics
BRCA2 Protein/*genetics
Pancreatic Neoplasms/*etiology
Animals ; Cell Cycle/genetics ; Chemoradiotherapy ; DNA Damage/drug effects ; DNA Repair/drug effects ; Disease Susceptibility ; Epigenesis, Genetic/drug effects ; Gene Expression Regulation/drug effects ; Humans ; Pancreatic Neoplasms/metabolism ; Pancreatic Neoplasms/pathology ; Pancreatic Neoplasms/therapy ; Poly(ADP-ribose) Polymerase Inhibitors/pharmacology ; Poly(ADP-ribose) Polymerases/metabolism ; Signal Transduction
Czasopismo naukowe
Tytuł :
The m A RNA demethylase FTO is a HIF-independent synthetic lethal partner with the VHL tumor suppressor.
Autorzy :
Xiao Y; Department of Radiation Oncology, Stanford University, Stanford, CA 94305.
Thakkar KN; Department of Radiation Oncology, Stanford University, Stanford, CA 94305.
Zhao H; Department of Urology, Stanford University, Stanford, CA 94305.
Broughton J; Mammoth Biosciences, South San Francisco, CA 94080.
Li Y; Department of Radiation Oncology, Stanford University, Stanford, CA 94305.
Seoane JA; Department of Medicine, Stanford University, Stanford, CA 94305.; Deparment of Genetics, Stanford University, Stanford, CA 94305.
Diep AN; Department of Radiation Oncology, Stanford University, Stanford, CA 94305.
Metzner TJ; Department of Urology, Stanford University, Stanford, CA 94305.
von Eyben R; Department of Radiation Oncology, Stanford University, Stanford, CA 94305.
Dill DL; Department of Computer Science, Stanford University, Stanford, CA 94305.
Brooks JD; Department of Urology, Stanford University, Stanford, CA 94305.
Curtis C; Department of Medicine, Stanford University, Stanford, CA 94305.; Deparment of Genetics, Stanford University, Stanford, CA 94305.
Leppert JT; Department of Urology, Stanford University, Stanford, CA 94305.
Ye J; Department of Radiation Oncology, Stanford University, Stanford, CA 94305.
Peehl DM; Deparment of Genetics, Stanford University, Stanford, CA 94305.; Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94158.
Giaccia AJ; Department of Radiation Oncology, Stanford University, Stanford, CA 94305.
Sinha S; Department of Computer Science, Stanford University, Stanford, CA 94305.
Rankin EB; Department of Radiation Oncology, Stanford University, Stanford, CA 94305; .; Department of Obstetrics and Gynecology, Stanford University, Stanford, CA 94305.
Pokaż więcej
Źródło :
Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2020 Sep 01; Vol. 117 (35), pp. 21441-21449. Date of Electronic Publication: 2020 Aug 19.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Synthetic Lethal Mutations*
Alpha-Ketoglutarate-Dependent Dioxygenase FTO/*genetics
Carcinoma, Renal Cell/*genetics
Kidney Neoplasms/*genetics
Von Hippel-Lindau Tumor Suppressor Protein/*genetics
Alpha-Ketoglutarate-Dependent Dioxygenase FTO/metabolism ; Amino Acid Transport System ASC/metabolism ; Animals ; Basic Helix-Loop-Helix Transcription Factors/metabolism ; Carcinoma, Renal Cell/metabolism ; Cell Line, Tumor ; Computer Simulation ; Humans ; Hypoxia-Inducible Factor 1/metabolism ; Kidney Neoplasms/metabolism ; Mice, Knockout ; Minor Histocompatibility Antigens/metabolism
Czasopismo naukowe
Tytuł :
Correcting an instance of synthetic lethality with a pro-survival sequence.
Autorzy :
Zhou DR; Department of Chemistry and Chemical Engineering, Royal Military College, Kingston, Ontario, Canada; Department of Anatomy and Cell Biology, McGill University, Montreal, Quebec, Canada.
Miller KA; Department of Chemistry and Chemical Engineering, Royal Military College, Kingston, Ontario, Canada.
Greenwood M; Department of Chemistry and Chemical Engineering, Royal Military College, Kingston, Ontario, Canada.
Boucher E; Department of Anatomy and Cell Biology, McGill University, Montreal, Quebec, Canada.
Mandato CA; Department of Anatomy and Cell Biology, McGill University, Montreal, Quebec, Canada.
Greenwood MT; Department of Chemistry and Chemical Engineering, Royal Military College, Kingston, Ontario, Canada. Electronic address: .
Pokaż więcej
Źródło :
Biochimica et biophysica acta. Molecular cell research [Biochim Biophys Acta Mol Cell Res] 2020 Sep; Vol. 1867 (9), pp. 118734. Date of Electronic Publication: 2020 May 07.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Synthetic Lethal Mutations*
Cell Survival/*genetics
Adaptor Proteins, Signal Transducing/metabolism ; Apoptosis ; Autophagy ; Humans ; LIM Domain Proteins/chemistry ; LIM Domain Proteins/genetics ; LIM Domain Proteins/metabolism ; Models, Biological ; Muscle Proteins/chemistry ; Muscle Proteins/genetics ; Muscle Proteins/metabolism ; Protein Binding ; Protein Interaction Domains and Motifs ; Reactive Oxygen Species/metabolism ; Saccharomyces cerevisiae/genetics ; Saccharomyces cerevisiae/metabolism ; Saccharomyces cerevisiae Proteins/metabolism ; bcl-2-Associated X Protein/metabolism
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies